Treatment of Relapsed/Refractory Pediatric Sarcomas With Gemcitabine and Docetaxel
Authors:
- Jaume MoraJMJaume Mora
- Cheeu Ofelia CruzCCCheeu Ofelia Cruz
- Andreu PararedaAPAndreu Parareda
- Carmen de TorresCTCarmen de Torres
- 1 October 2009
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 31 (10) , 723-729
Abstract
In this report we describe experience with gemcitabine-docetaxel in pediatric patients with relapsed or refractory sarcomas. Ten relapsed/refractory pediatric sarcoma patients including 6 Ewing sarcoma, 2 synovial sarcoma, 1 osteosarcoma, and 1 undifferentiated sarcoma, were treated prospectively, in an outpatient setting, with gemcitabine 1000 mg/m over 90 minutes on day 1 and 8, and docetaxel 100 mg/m over 2 to 4 hours on day 8 of a 21-day cycle, as an investigational rescue therapy. The patients (ages 4 to 18) received a total of 70 cycles of therapy (median 6 cycles; range: 4 to 10 y). All symptomatic patients responded clinically to the new regimen. By Response Evaluation Criteria in Solid Tumors criteria, 4 (40%) patients had a complete response (CR), 1 (10%) had a partial response (PR), 3 (30%) had stable disease (SD), and 2 (20%) had a progressive disease (PD), which provides an objective response rate (CR+PR) of 50%. Median duration of response (CR+PR+SD) was 10 months (range: 6 to 32+ mo). Five out of the 10 patients (50%) are alive, with a median follow-up of 48 months from diagnosis. Mild toxicities (no grades 3 to 4) were encountered and managed in the ambulatory setting. The gemcitabine-docetaxel regimen demonstrated antitumor activity against advanced pediatric (mainly Ewing) sarcomas, allowing for good quality of life. Evaluation in a large, formal phase 2 trials for Ewing patients is ongoing.Keywords
This publication has 19 references indexed in Scilit:
- Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002Journal of Clinical Oncology, 2007
- Signature-Based Small Molecule Screening Identifies Cytosine Arabinoside as an EWS/FLI Modulator in Ewing SarcomaPLOS Medicine, 2007
- Docetaxel and gemcitabine combination in 133 advanced soft‐tissue sarcomas: A retrospective analysisInternational Journal of Cancer, 2006
- Phase II investigation of docetaxel in pediatric patients with recurrent solid tumorsCancer, 2006
- Phase I Trial and Pharmacokinetics of Gemcitabine in Children With Advanced Solid TumorsJournal of Clinical Oncology, 2004
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Laboratory and Clinical Evidence of Synergistic Cytotoxicity of Sequential Treament With Gemcitabine Followed by Docetaxel in the Treatment of SarcomaJournal of Clinical Oncology, 2004
- High-dose therapy with autologous stem cell rescue for pediatric sarcomasCurrent Opinion in Oncology, 2004
- Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II TrialJournal of Clinical Oncology, 2002
- Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial.Journal of Clinical Oncology, 1997